



an Open Access Journal by MDPI

Novel Antibacterial, Antibiofilm and Anti-virulence Candidates

Guest Editors:

submissions:

Dr. Wael Hegazy

Dr. Amr S. Abu Lila

Message from the Guest Editors

The growing microbial resistance to antibiotics is an increasingly challenging issue that global health faces. The dwindling discovery of new antibiotics worsens the situation and mandates new approaches and strategies to Dr. Tarek S. Ibrahim conquer microbial resistance. Bacteria recruit diverse virulence factors and employ several systems to control the regulation of these virulence arsenals. Among the most Deadline for manuscript resistant microbial phenotypes, bacterial biofilms constitute a huge obstacle against efficient antibiotic closed (30 November 2023) treatments. Targeting bacterial virulence and diminishing biofilms greatly attenuates bacteria and eases their eradication through antibiotics. Targeting virulence can be achieved by targeting virulence-controlling systems. Among the most involved virulence-controlling systems, quorum sensing (QS) plays a crucial role in orchestrating the production of bacterial virulence factors and biofilms. Moreover, several approaches have been suggested to eradicate bacterial biofilms and inhibit bacterial virulence. This issue focuses on the discovery of new antibacterial and antibiofilm candidates to serve as adjuvants to antibiotics in the treatment of aggressive infections.



Specialsue





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA 2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research. biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine* (*miscellaneous*))

Contact Us

Biomedicines Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 www.mdpi.com mdpi.com/journal/biomedicines biomedicines@mdpi.com X@Biomed_MDPI